Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction — Josep Gómez‐Lara (2013) | RDL Network
Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction
American Heart Journal 166(1): 119-126.e1
Article 2013 English
Authors
JG
Josep Gómez‐Lara
SB
Salvatore Brugaletta
JG
Joan Antoni Gómez‐Hospital
Abstract
2 min read
Background
ST-elevation myocardial infarctions (STEMI) caused by proximal left-anterior descending (LAD) lesions have more myocardium at risk and worse outcomes than those located in other segments. The aim is to compare outcomes of patients with STEMI and proximal-LAD lesions treated with bare-metal stents (BMS) versus everolimus-eluting stents (EES).
Methods
The EXAMINATION trial randomized 1498 STEMI patients to BMS versus EES. The primary end point was the patient-oriented combined of all-cause death, any-recurrent myocardial infarction (MI) and any-revascularization. The secondary end point included the device-oriented combined of cardiac death, target-vessel MI and target-lesion revascularization (TLR).
Results
STEMI with a proximal-LAD occlusion was observed in 290 patients (BMS = 132 and EES = 158). Both groups were similar except for diabetes (12.9% vs 24.1%; P = .016). At 1 year, the primary end point was observed in 18.9% and 9.5% of patients treated with BMS and EES, respectively (P = .023). The secondary end point was observed in 11.4% and 5.1%, respectively (P = .053). There were no differences in cardiac death (4.5% vs 3.8%; P = .750) and MI (1.5% vs 0%; P = .121). BMS had higher rate of TLR compared to EES (6.8% vs 1.3%; P = .014).
Patients with proximal-LAD STEMI had higher mortality than patients with non proximal-LAD STEMI (5.5% vs 2.9%; P = .027). Proximal-LAD lesions treated with BMS tended to increase the risk of the primary end point compared with other segments (18.9% vs 13.0%; P = .079). However, EES implanted in proximal-LAD had similar outcomes compared with other locations (9.5% vs 12.0%; P = .430). Adjusting for confounders, the interaction between BMS and proximal-LAD location was associated with the primary end point.
Conclusion
Patients with STEMI and proximal-LAD lesions treated with EES have better outcomes compared with BMS at 1 year. Although further investigations are required, it seems reasonable to consider EES for proximal-LAD STEMI-lesions.
Manel Sabaté, Ángel Cequier, Andrés Íñiguez, Antonio Serra, Rosana Hernández‐Antolín, Vicente Mainar, Marco Valgimigli, Maurizio Tespili, Pieter den Heijer, Armando Bethencourt, Nicolás Vazquez, Joan Antoni Gómez‐Hospital, José Antonio Baz, Victoria Martín‐Yuste, Robert‐Jan van Geuns, Fernándo Alfonso, Pascual Bordes, Matteo Tebaldi, Mónica Masotti, Antonio Silvestro, Bianca Backx, Salvatore Brugaletta, Gerrit Anne van Es, Patrick W. Serruys
Salvatore Brugaletta, Tommaso Gori, Adrian F. Low, Petr Toušek, Eduardo Pinar, Josep Gómez‐Lara, Giancarla Scalone, Eberhard Schulz, Mark Y. Chan, Viktor Kočka, José Hurtado, Juan Antoni Gomez-Hospital, Thomas Münzel, Chi‐Hang Lee, Ángel Cequier, Mariano Valdés, Petr Widimský, Patrick W. Serruys, Manel Sabaté
Pilar Jiménez‐Quevedo, Salvatore Brugaletta, Ángel Cequier, Andrés Íñiguez, Antonio Serra, Vicente Mainar, Gianluca Campo, Maurizio Tespili, Luis Nombela‐Franco, María Del Trigo, Nieves Gonzalo, Javier Escaned, Pablo Salinas, Iván J. Núñez‐Gil, Cristina Fernández, Antonio Fernández-Ortı́z, Carlos Macaya, Patrick W. Serruys, Manel Sabaté
Discussion(0)
No comments yet. Be the first to comment.